Medicus Pharma (MDCX) Competitors $3.40 +0.02 (+0.59%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock MDCX vs. ACTU, CRBU, NMRA, VXRT, NKTX, IKT, GLSI, FTLF, KRRO, and TARAShould you be buying Medicus Pharma stock or one of its competitors? The main competitors of Medicus Pharma include Actuate Therapeutics (ACTU), Caribou Biosciences (CRBU), Neumora Therapeutics (NMRA), Vaxart (VXRT), Nkarta (NKTX), Inhibikase Therapeutics (IKT), Greenwich LifeSciences (GLSI), FitLife Brands (FTLF), Korro Bio (KRRO), and Protara Therapeutics (TARA). These companies are all part of the "pharmaceutical products" industry. Medicus Pharma vs. Its Competitors Actuate Therapeutics Caribou Biosciences Neumora Therapeutics Vaxart Nkarta Inhibikase Therapeutics Greenwich LifeSciences FitLife Brands Korro Bio Protara Therapeutics Actuate Therapeutics (NASDAQ:ACTU) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership. Is ACTU or MDCX more profitable? Actuate Therapeutics' return on equity of 0.00% beat Medicus Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A N/A -339.73% Medicus Pharma N/A -380.03%-224.22% Does the media favor ACTU or MDCX? In the previous week, Medicus Pharma had 2 more articles in the media than Actuate Therapeutics. MarketBeat recorded 4 mentions for Medicus Pharma and 2 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.69 beat Medicus Pharma's score of 0.79 indicating that Actuate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Medicus Pharma 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, ACTU or MDCX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$27.28MN/AN/AMedicus PharmaN/AN/A-$11.16M-$1.16-2.93 Do analysts recommend ACTU or MDCX? Actuate Therapeutics currently has a consensus price target of $20.50, indicating a potential upside of 241.10%. Medicus Pharma has a consensus price target of $23.50, indicating a potential upside of 591.18%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than Actuate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Medicus Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 SummaryMedicus Pharma beats Actuate Therapeutics on 6 of the 8 factors compared between the two stocks. Get Medicus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MDCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDCX vs. The Competition Export to ExcelMetricMedicus PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.88M$2.92B$5.53B$9.03BDividend YieldN/A2.44%5.24%4.07%P/E Ratio-2.9320.3027.1920.03Price / SalesN/A251.54414.39108.98Price / CashN/A41.7026.2128.59Price / Book11.727.397.925.55Net Income-$11.16M-$55.04M$3.17B$248.49M7 Day Performance13.71%3.01%2.18%5.37%1 Month Performance23.19%-0.21%1.25%6.63%1 Year PerformanceN/A4.48%33.90%21.20% Medicus Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDCXMedicus Pharma2.5158 of 5 stars$3.40+0.6%$23.50+591.2%N/A$45.88MN/A-2.93N/AUpcoming EarningsGap UpHigh Trading VolumeACTUActuate Therapeutics2.9841 of 5 stars$6.44-4.6%$20.50+218.3%N/A$132.43MN/A0.0010Positive NewsCRBUCaribou Biosciences2.0325 of 5 stars$1.42+0.7%$8.50+498.6%-15.0%$131.14M$9.99M-0.88100News CoverageAnalyst UpgradeNMRANeumora Therapeutics2.3787 of 5 stars$0.81-0.1%$9.29+1,049.4%-92.1%$130.76MN/A-0.50108VXRTVaxart2.2371 of 5 stars$0.54-3.9%$3.00+457.6%-34.4%$127.85M$28.70M-1.99120Gap DownNKTXNkarta2.0617 of 5 stars$1.78+1.7%$14.33+705.2%-66.1%$124.18MN/A-1.18140IKTInhibikase Therapeutics1.3227 of 5 stars$1.67+0.6%$6.50+289.2%+62.9%$124.15M$260K-0.636GLSIGreenwich LifeSciences1.4566 of 5 stars$9.00-0.6%$39.00+333.3%-39.9%$120.98MN/A-7.143FTLFFitLife Brands4.0216 of 5 stars$12.81-0.2%$20.50+60.0%-12.7%$120.58M$64.47M15.2520KRROKorro Bio1.686 of 5 stars$11.94-5.9%$102.43+757.9%-64.7%$119.17M$2.27M-1.2670TARAProtara Therapeutics1.7879 of 5 stars$2.89-5.6%$20.50+609.3%+40.4%$118.06MN/A-1.6830 Related Companies and Tools Related Companies Actuate Therapeutics Alternatives Caribou Biosciences Alternatives Neumora Therapeutics Alternatives Vaxart Alternatives Nkarta Alternatives Inhibikase Therapeutics Alternatives Greenwich LifeSciences Alternatives FitLife Brands Alternatives Korro Bio Alternatives Protara Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDCX) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicus Pharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
